Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Unicycive Therapeutics Inc (UNCY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.48-7.20%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.83 → 1.41 EPS · FY ending Dec 31, 2027 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for UNCY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain financial discipline and manage cash burn | Management aims to control cash burn, with operating losses near -$8.4M and cash flow around -$6.2M. | Intact | Operating loss or cash burn worsens beyond -$8.4M and -$6.2M respectively | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, approval-and-launch-driven biotech thesis, not an established earnings compounder. The thesis is still in watch territory: management remains focused on OLC, but confidence in the evidence is low and recent financial performance is weak.
The available valuation evidence indicates UNCY is expensive versus peers, with optionality driving the valuation gap. The evidence does not specify exactly what approval or launch expectations the market assumes, so the expectations gap is unclear.
Near term, earnings are erratic and the estimated miss risk is elevated, while recent performance has lagged its industry cohort. For the multi-year thesis, management says its resubmitted OLC application includes a new manufacturing vendor and reports cash runway into 2027, but launch preparation is still mixed and expenses have risen.
The main swing factor is whether OLC secures FDA approval and reaches launch, alongside management’s ability to build commercial readiness and manage cash. A guidance cut would be a meaningful negative; continued strength among healthcare bellwethers could support the sector backdrop, while weaker jobs data could weigh on healthcare names.
Over the next 1 to 3 years, UNCY’s thesis depends on turning OLC approval and launch preparation into progress while managing elevated risk and weak recent performance. The evidence is limited and valuation is expensive versus peers. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| If clinical progress accelerates, earnings could improve from -$1.67 EPS in 2026 to positive $5.15 EPS in 2027. |
| Intact |
| Failure to meet key clinical milestones or trial delays in 2026 |
FDA accepted OLC resubmission (qualitative milestone met) FDA accepted Unicycive's OLC resubmission in Oct 2026, advancing the drug toward approval despite a concurrent securities lawsuit. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
EPS improvement from losses to profitability | If clinical progress accelerates, earnings could improve from -$1.67 EPS in 2026 to positive $5.15 EPS in 2027. | Improving | EPS remains negative beyond 2027 or worsens from current guidance | Diluted EPS: $-0.06 per share FY2026-Q2; GAAP. Published target: EPS improves from -$1.67 in 2026 to positive EPS above $0 by end of 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 12, 2026-0.06 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$4.62 → $1.41 · observed estimates
$0.29B → $0.13B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-25 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-26 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-27 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-28 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-29 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-30 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-07-31 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-01 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-02 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-03 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-04 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-05 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-06 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-08 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-09 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-10 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-12 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-13 | $5.15 | $288,379,780 | 8 / 9 |
| 2026-08-14 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-15 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-16 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-17 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-18 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-19 | $4.62 | $288,379,778 | 6 / 7 |
| 2026-08-20 | $1.80 | $150,253,556 | 7 / 7 |
| 2026-08-21 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-22 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-23 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-24 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-25 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-26 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-27 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-28 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-29 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-30 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-08-31 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-01 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-02 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-03 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-04 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-05 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-06 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-07 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-08 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-09 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-10 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-11 | $1.81 | $150,253,556 | 6 / 7 |
| 2026-09-12 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-13 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-14 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-15 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-16 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-17 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-18 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-19 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-20 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-21 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-22 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-23 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-24 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-25 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-26 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-27 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-28 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-29 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-09-30 | $1.81 | $150,253,556 | 7 / 7 |
| 2026-10-01 | $1.83 | $149,503,778 | 7 / 7 |
| 2026-10-02 | $1.83 | $149,503,778 | 7 / 7 |
| 2026-10-03 | $1.83 | $149,503,778 | 7 / 7 |
| 2026-10-04 | $1.83 | $149,503,778 | 7 / 7 |
| 2026-10-05 | $1.83 | $149,503,778 | 7 / 7 |
| 2026-10-06 | $1.83 | $149,503,778 | 7 / 7 |
| 2026-10-07 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-08 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-09 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-10 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-11 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-12 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-13 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-14 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-15 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-16 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-17 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-18 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-19 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-20 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-21 | $1.65 | $143,194,250 | 7 / 7 |
| 2026-10-22 | $1.64 | $143,194,225 | 7 / 7 |
| 2026-10-23 | $1.64 | $143,194,225 | 7 / 7 |
| 2026-10-24 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-25 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-26 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-27 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-28 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-29 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-30 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-10-31 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-11-01 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-11-02 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-11-03 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-11-04 | $1.41 | $131,356,725 | 7 / 7 |
| 2026-11-05 | $1.41 | $131,356,725 | 7 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.